Ginkgo Bioworks Holdings Inc Stock Price, News & Analysis

On June 6, 2022, Ginkgo Bioworks (NYSE: DNA) announced the acquisition of assets from Bitome, a leader in real-time metabolite monitoring technology. This technology uses machine learning to enhance bioprocess optimization by providing continuous monitoring of cell culture media. The integration aims to streamline the development timelines of Ginkgo's cell programming platform, potentially accelerating product readiness. Ginkgo's co-founder highlighted that this acquisition will significantly improve strain testing at scale, addressing a critical bottleneck in synthetic biology.

Ginkgo Bioworks (NYSE: DNA) will participate in William Blair's 42nd Annual Growth Stock Conference on June 9, 2022, at 11:20 a.m. CT. The conference aims to showcase growth stocks to investors and provide insights into Ginkgo's cell programming platform, which serves various markets from agriculture to pharmaceuticals. Details about the event, including a webcast link and a replay, can be found on the company's investor relations website.

Ginkgo Bioworks (NYSE: DNA) and First Serv have announced a non-binding MOU to develop biosecurity capabilities in Qatar, aiming to establish a global pathogen monitoring network. This partnership leverages Ginkgo's biosecurity platform and Qatar's investments in biotechnology to enhance pathogen detection and response capabilities. The initiative is intended to position Doha as a critical node for global pathogen monitoring, facilitating informed public health decisions amid potential biological threats. This collaboration marks Ginkgo's strategic international expansion in biosecurity.

Ginkgo Bioworks reported Q1 2022 revenue of $168 million, up 282% YoY, primarily driven by its biosecurity business, which generated $147 million. The company added 11 new Cell Programs, reflecting 175% growth. Full-year revenue guidance has increased from $325-$340 million to $375-$390 million. Ginkgo maintains a $1.5 billion cash balance, supporting future growth initiatives. However, it experienced a significant loss of $(675 million) in operations due to stock-based compensation. The company anticipates adding 60 new Cell Programs in 2022.

Evo Foods and Ginkgo Bioworks have announced a partnership aimed at developing animal-free egg proteins to enhance Evo's product line. This initiative comes in response to increasing consumer demand for sustainable food alternatives. Evo, founded in 2020, aims to end animal agriculture by creating superior substitutes for animal products, starting with eggs. Utilizing Ginkgo's advanced Cell Development Kits, Evo seeks to innovate and improve the culinary properties of egg substitutes. Both companies emphasize their commitment to sustainability and meeting market needs.

Ginkgo Bioworks (NYSE: DNA) will host a presentation and Q&A session on May 16, 2022, at 4:30 p.m. ET, to review its first-quarter performance ending March 31, 2022. The session will be accessible via Ginkgo's investor relations website, where a replay will also be available. This meeting aims to provide investors with insights into Ginkgo's business metrics and future projections, reinforcing its position in the biotechnology sector with applications in various markets including food, agriculture, and pharmaceuticals.

Ginkgo Bioworks (NYSE: DNA) plans to enhance its agricultural biologicals platform by acquiring Bayer's 175,000-square-foot West Sacramento R&D site and integrating the Joyn Bio joint-venture. This transaction aims to support agricultural biologicals R&D from discovery to field trials, with Bayer continuing as an anchor customer through a multi-year collaboration focused on nitrogen fixation and crop protection. The deal is expected to close by the end of 2022, pending regulatory approvals.

Light Bio has partnered with Ginkgo Bioworks (NYSE: DNA) to enhance the performance of bioluminescent plants. Ginkgo will apply its plant cell assays to improve the luminescent efficiency of Light Bio's glowing plants, which utilize enzymes derived from bioluminescent mushrooms. CEO Keith Wood of Light Bio expressed enthusiasm about the collaboration aiming for significant improvements in luminous output. The partnership leverages Ginkgo's advanced biotechnology capabilities to create innovative biodesigns, opening new market opportunities in ornamental plant applications.

FREDsense Technologies partners with Ginkgo Bioworks (NYSE: DNA) to develop biosensors for water quality monitoring. This collaboration aims to create four unique microbial strain biosensors compatible with FREDsense's portable hardware, allowing for real-time detection of harmful molecules in water sources. The partnership addresses the increasing demand for efficient water testing solutions and aims to enhance environmental and public health. CEOs from both companies express excitement about leveraging synthetic biology for critical water safety applications.